The Europe Mobile ECG Devices Market would witness market growth of 11.8% CAGR during the forecast period (2023-2030). In the year 2020, the Europe market's volume surged to 1,789.0 thousand units, showcasing a growth of 17.2% (2019-2022).
A number of compelling factors in the healthcare landscape are driving a significant upswing in the market. The demand for cardiac monitoring tools, such as mobile ECG devices, is rising due to the growing number of AF/AFL (Atrial Fibrillation/Atrial Flutter) patients. AFL-related deaths and disability-adjusted years are found to be significantly correlated with high systolic blood pressure, alcohol use, smoking, elevated body mass index, and high-sodium diets. These risk factors highlight the importance of mobile ECG devices in cardiac healthcare since they provide effective and convenient monitoring and early detection.
The market has been greatly influenced by the increasing prevalence of cardiovascular diseases (CVDs) regionally. As one of the leading causes of morbidity and death, cardiovascular diseases must be detected early and continuously monitored in order to be effectively managed. Mobile ECG devices have emerged as essential tools for individuals at risk of CVDs, as well as those with existing heart conditions, enabling them to monitor their heart health proactively.
The COVID-19 pandemic has further highlighted the importance of mobile ECG devices. With the healthcare system under strain and patients hesitant to visit hospitals, individuals turned to telehealth solutions for remote monitoring and consultations. Mobile ECG devices played a vital role in this transition, allowing healthcare providers to remotely assess and monitor their patient's cardiac health, ensuring continuity of care during challenging times.
Europe, like many other regions, is experiencing a demographic shift characterized by an aging population. As individuals age, the risk of cardiovascular diseases (CVDs) and heart-related issues increases. Mobile ECG devices offer a non-invasive and accessible means of continuous cardiac monitoring, aligning with the healthcare needs of the elderly population.
According to Eurostat, by the year 2050, 129.8 million older people will live in the EU-27, up from 90.5 million at the beginning of 2019. In the EU region, older people are 65 or older. In the EU-27, it is anticipated that the population between the ages of 75 and 84 will rise by 56.1% during this time, while that between the ages of 65 and 74 is expected to rise by 16.6%. On the other hand, according to the most recent estimates, by 2050, there will be 13.5% fewer people in the EU-27 who are under 55. As the region continues to prioritize heart health and remote patient monitoring, the demand for mobile ECG devices is expected to grow, making them an integral component of modern cardiac care in Europe.
The Germany market dominated the Europe Mobile ECG Devices Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $306.8 Million by 2030. The UK market is experiencing a CAGR of 10.7% during (2023 - 2030). Additionally, The France market would exhibit a CAGR of 12.6% during (2023 - 2030).
Based on Modality, the market is segmented into Handheld, Band, Pen, and Others. Based on End-use, the market is segmented into Hospitals & Diagnostic Centers, Ambulatory Care, and Homecare. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include New York Plastic Surgical Group, PC (Long Island Plastic Surgical Group), Nihon Kohden Corporation, GE HealthCare Technologies, Inc., Medtronic PLC, iRhythm Technologies, Inc., Koninklijke Philips N.V., OMRON Corporation, Nureca Limited (Dr Trust), EMAY, and AliveCor, Inc.
A number of compelling factors in the healthcare landscape are driving a significant upswing in the market. The demand for cardiac monitoring tools, such as mobile ECG devices, is rising due to the growing number of AF/AFL (Atrial Fibrillation/Atrial Flutter) patients. AFL-related deaths and disability-adjusted years are found to be significantly correlated with high systolic blood pressure, alcohol use, smoking, elevated body mass index, and high-sodium diets. These risk factors highlight the importance of mobile ECG devices in cardiac healthcare since they provide effective and convenient monitoring and early detection.
The market has been greatly influenced by the increasing prevalence of cardiovascular diseases (CVDs) regionally. As one of the leading causes of morbidity and death, cardiovascular diseases must be detected early and continuously monitored in order to be effectively managed. Mobile ECG devices have emerged as essential tools for individuals at risk of CVDs, as well as those with existing heart conditions, enabling them to monitor their heart health proactively.
The COVID-19 pandemic has further highlighted the importance of mobile ECG devices. With the healthcare system under strain and patients hesitant to visit hospitals, individuals turned to telehealth solutions for remote monitoring and consultations. Mobile ECG devices played a vital role in this transition, allowing healthcare providers to remotely assess and monitor their patient's cardiac health, ensuring continuity of care during challenging times.
Europe, like many other regions, is experiencing a demographic shift characterized by an aging population. As individuals age, the risk of cardiovascular diseases (CVDs) and heart-related issues increases. Mobile ECG devices offer a non-invasive and accessible means of continuous cardiac monitoring, aligning with the healthcare needs of the elderly population.
According to Eurostat, by the year 2050, 129.8 million older people will live in the EU-27, up from 90.5 million at the beginning of 2019. In the EU region, older people are 65 or older. In the EU-27, it is anticipated that the population between the ages of 75 and 84 will rise by 56.1% during this time, while that between the ages of 65 and 74 is expected to rise by 16.6%. On the other hand, according to the most recent estimates, by 2050, there will be 13.5% fewer people in the EU-27 who are under 55. As the region continues to prioritize heart health and remote patient monitoring, the demand for mobile ECG devices is expected to grow, making them an integral component of modern cardiac care in Europe.
The Germany market dominated the Europe Mobile ECG Devices Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $306.8 Million by 2030. The UK market is experiencing a CAGR of 10.7% during (2023 - 2030). Additionally, The France market would exhibit a CAGR of 12.6% during (2023 - 2030).
Based on Modality, the market is segmented into Handheld, Band, Pen, and Others. Based on End-use, the market is segmented into Hospitals & Diagnostic Centers, Ambulatory Care, and Homecare. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include New York Plastic Surgical Group, PC (Long Island Plastic Surgical Group), Nihon Kohden Corporation, GE HealthCare Technologies, Inc., Medtronic PLC, iRhythm Technologies, Inc., Koninklijke Philips N.V., OMRON Corporation, Nureca Limited (Dr Trust), EMAY, and AliveCor, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Modality (Volume, Thousand Units, USD Billion, 2019-2030)- Handheld
- Band
- Pen
- Others
- Hospitals & Diagnostic Centers
- Ambulatory Care
- Homecare
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- New York Plastic Surgical Group, PC (Long Island Plastic Surgical Group)
- Nihon Kohden Corporation
- GE HealthCare Technologies, Inc.
- Medtronic PLC
- iRhythm Technologies, Inc.
- Koninklijke Philips N.V.
- OMRON Corporation
- Nureca Limited (Dr Trust)
- EMAY
- AliveCor, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Europe Mobile ECG Devices Market, by Modality
Chapter 6. Europe Mobile ECG Devices Market, by End-use
Chapter 7. Europe Mobile ECG Devices Market, by Country
Chapter 8. Company Profiles
Companies Mentioned
- New York Plastic Surgical Group, PC (Long Island Plastic Surgical Group)
- Nihon Kohden Corporation
- GE HealthCare Technologies, Inc.
- Medtronic PLC
- iRhythm Technologies, Inc.
- Koninklijke Philips N.V.
- OMRON Corporation
- Nureca Limited (Dr Trust)
- EMAY
- AliveCor, Inc.
Methodology
LOADING...
